These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24670619)

  • 1. Evaluation of Mdh1 protein as an antigenic candidate for a vaccine against candidiasis.
    Shibasaki S; Aoki W; Nomura T; Karasaki M; Sewaki T; Ueda M
    Biocontrol Sci; 2014; 19(1):51-5. PubMed ID: 24670619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice.
    Spellberg BJ; Ibrahim AS; Avenissian V; Filler SG; Myers CL; Fu Y; Edwards JE
    Infect Immun; 2005 Sep; 73(9):6191-3. PubMed ID: 16113347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with Secreted Aspartyl Proteinase 2 Protein from
    Shukla M; Rohatgi S
    Infect Immun; 2020 Sep; 88(10):. PubMed ID: 32661125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An oral vaccine against candidiasis generated by a yeast molecular display system.
    Shibasaki S; Aoki W; Nomura T; Miyoshi A; Tafuku S; Sewaki T; Ueda M
    Pathog Dis; 2013 Dec; 69(3):262-8. PubMed ID: 23873745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomal Fba and Met6 peptide vaccination protects mice from disseminated candidiasis.
    Huang W-C; Eberle K; Colon JR; Lovell JF; Xin H
    mSphere; 2024 Jul; 9(7):e0018924. PubMed ID: 38904363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased resistance in BALB/c mice to reinfection with Candida albicans is due to immunoneutralization of a virulence-associated immunomodulatory protein.
    Tavares D; Ferreira P; Arala-Chaves M
    Microbiology (Reading); 2003 Feb; 149(Pt 2):333-339. PubMed ID: 12624195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel Candida albicans Als3, Hwp1 and Met6 derived complex peptide protects mice against hematogenously induced candidiasis.
    Diez A; Arrieta-Aguirre I; Carrano G; Fernandez-de-Larrinoa I; Moragues MD
    Vaccine; 2024 Aug; 42(20):125990. PubMed ID: 38789371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunisation with the glycolytic enzyme enolase confers effective protection against Candida albicans infection in mice.
    Li Wq; Hu Xc; Zhang X; Ge Y; Zhao S; Hu Y; Ashman RB
    Vaccine; 2011 Jul; 29(33):5526-33. PubMed ID: 21645574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hybrid phage displaying SLAQVKYTSASSI induces protection against Candida albicans challenge in BALB/c mice.
    Wang Y; Su Q; Dong S; Shi H; Gao X; Wang L
    Hum Vaccin Immunother; 2014; 10(4):1057-63. PubMed ID: 24448202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Horizontal transmission of Candida albicans and evidence of a vaccine response in mice colonized with the fungus.
    Cutler JE; Corti M; Lambert P; Ferris M; Xin H
    PLoS One; 2011; 6(7):e22030. PubMed ID: 21818288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.
    Ibrahim AS; Luo G; Gebremariam T; Lee H; Schmidt CS; Hennessey JP; French SW; Yeaman MR; Filler SG; Edwards JE
    Vaccine; 2013 Nov; 31(47):5549-56. PubMed ID: 24063977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis.
    Cárdenas-Freytag L; Cheng E; Mayeux P; Domer JE; Clements JD
    Infect Immun; 1999 Feb; 67(2):826-33. PubMed ID: 9916097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effect of fungal extracellular vesicles against murine candidiasis.
    Vargas G; Honorato L; Guimarães AJ; Rodrigues ML; Reis FCG; Vale AM; Ray A; Nosanchuk JD; Nimrichter L
    Cell Microbiol; 2020 Oct; 22(10):e13238. PubMed ID: 32558196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active immunizations with peptide-DC vaccines and passive transfer with antibodies protect neutropenic mice against disseminated candidiasis.
    Xin H
    Vaccine; 2016 Jan; 34(2):245-251. PubMed ID: 26620842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of a genetically engineered Candida albicans tet-NRG1 strain as an experimental live attenuated vaccine against hematogenously disseminated candidiasis.
    Saville SP; Lazzell AL; Chaturvedi AK; Monteagudo C; Lopez-Ribot JL
    Clin Vaccine Immunol; 2009 Mar; 16(3):430-2. PubMed ID: 19144791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection against systemic infections with various Candida species elicited by vaccination with Candida albicans ribosomes.
    Segal E; Nussbaum S; Barr-Nea L
    Sabouraudia; 1985 Aug; 23(4):275-85. PubMed ID: 3901330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Post-Vaccination Phagocytic Activation Using Candida albicans Killing Assays.
    Li W; Hu Y
    Methods Mol Biol; 2017; 1625():313-326. PubMed ID: 28584999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A highly immunogenic recombinant and truncated protein of the secreted aspartic proteases family (rSap2t) of Candida albicans as a mucosal anticandidal vaccine.
    Sandini S; La Valle R; Deaglio S; Malavasi F; Cassone A; De Bernardis F
    FEMS Immunol Med Microbiol; 2011 Jul; 62(2):215-24. PubMed ID: 21535228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two Candida mannan vaccines: the role of complement in protection against disseminated candidiasis.
    Han Y; Rhew KY
    Arch Pharm Res; 2012 Nov; 35(11):2021-7. PubMed ID: 23212645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testing Antifungal Vaccines in an Animal Model of Invasive Candidiasis and in Human Mucosal Candidiasis.
    Segal E
    Methods Mol Biol; 2017; 1625():343-353. PubMed ID: 28585001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.